Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MOBOCERTINIB: 715 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
715
Total FAERS Reports
320 (44.8%)
Deaths Reported
227
Hospitalizations
715
As Primary/Secondary Suspect
10
Life-Threatening
2
Disabilities
Sep 15, 2021
FDA Approved
Discontinued
Status

FDA Application: 215310 ·

Patent Expires: May 13, 2035 · First Report: 20160914 · Latest Report: 20250430

What Are the Most Common MOBOCERTINIB Side Effects?

#1 Most Reported
Diarrhoea
309 reports (43.2%)
#2 Most Reported
Death
160 reports (22.4%)
#3 Most Reported
Rash
106 reports (14.8%)

All MOBOCERTINIB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Diarrhoea 309 43.2% 88 133
Death 160 22.4% 160 40
Rash 106 14.8% 20 37
Non-small cell lung cancer 96 13.4% 43 21
Nausea 85 11.9% 19 39
Decreased appetite 80 11.2% 27 36
Lung neoplasm malignant 74 10.4% 32 14
Vomiting 74 10.4% 29 47
Fatigue 66 9.2% 17 32
Asthenia 56 7.8% 22 33
Weight decreased 54 7.6% 9 21
Dry skin 52 7.3% 7 17
Stomatitis 45 6.3% 8 19
Pneumonia 44 6.2% 20 35
Product dose omission issue 42 5.9% 11 24
Metastases to central nervous system 41 5.7% 24 15
Off label use 40 5.6% 15 18
Malignant neoplasm progression 39 5.5% 15 6
Dehydration 37 5.2% 6 23
Drug ineffective 32 4.5% 5 7

Who Reports MOBOCERTINIB Side Effects? Age & Gender Data

Gender: 66.1% female, 33.9% male. Average age: 65.7 years. Most reports from: US. View detailed demographics →

Is MOBOCERTINIB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2016 1 1 1
2017 1 1 1
2018 1 0 1
2019 2 0 2
2020 9 4 4
2021 71 33 33
2022 163 76 74
2023 124 45 59
2024 13 7 6
2025 3 0 2

View full timeline →

What Is MOBOCERTINIB Used For?

IndicationReports
Lung neoplasm malignant 291
Product used for unknown indication 170
Non-small cell lung cancer 169
Lung adenocarcinoma 29
Egfr gene mutation 26
Non-small cell lung cancer metastatic 14
Lung carcinoma cell type unspecified stage iv 12
Lung cancer metastatic 10
Lung adenocarcinoma stage iv 9
Non-small cell lung cancer stage iv 9

MOBOCERTINIB vs Alternatives: Which Is Safer?

MOBOCERTINIB vs MOCLOBEMIDE MOBOCERTINIB vs MODAFINIL MOBOCERTINIB vs MOGAMULIZUMAB MOBOCERTINIB vs MOGAMULIZUMAB-KPKC MOBOCERTINIB vs MOLNUPIRAVIR MOBOCERTINIB vs MOLSIDOMINE MOBOCERTINIB vs MOMELOTINIB MOBOCERTINIB vs MOMETASONE MOBOCERTINIB vs MOMETASONE FUROATE MOBOCERTINIB vs MOMETASONE FUROATE\OLOPATADINE

Official FDA Label for MOBOCERTINIB

Official prescribing information from the FDA-approved drug label.